2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 10, 2015

9:00AM-11:00AM: Abstract Number: 2175

Comparative Study Between Coagucheck XS Versus Standard Laboratory Practice Protrombine Time for Monitoring Anticoagulant Therapy in Patients with Antiphospholipid Syndrome

Antiphospholipid Syndrome: Basic Science

9:00AM-11:00AM: Abstract Number: 2693

Comparing Eight Year Clinical and Radiographic Outcome in Two Cohorts of Patients with Rheumatoid Arthritis

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2636

Comparison of Arterial Health in Patients with Rheumatoid Arthritis to a Population-Based Cohort

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2407

Comparison of Knee Osteoarthritis Treatment in the Non-Obese Versus Obese Populations Across Different Medical Specialties

Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research

9:00AM-11:00AM: Abstract Number: 2670

Comparison of M-DAS and DAS28, Two Composite Scores for Prediction of Structural Damages in Rheumatoid Arthritis: Data from the Espoir Cohort

Rheumatoid Arthritis - Clinical Aspects Poster Session III

9:00AM-11:00AM: Abstract Number: 2402

Comparison of Synovitis on MRI and Pain in Knee Osteoarthritis Patients with and without Chondrocalcinosis: Data from the Osteoarthritis Initiative (OAI)

Osteoarthritis - Clinical Aspects Poster II: Biomarkers, Biomechanics and Health Services Research

9:00AM-11:00AM: Abstract Number: 2746

Comparison Study of Tests Available to Monitor Tocilizumab Therapy in Rheumatic Patients

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2242

Compliance with Allopurinol Among Hypertensive Patients with Gout Diagnosis and the Relationship to Onset of End-Stage Renal Disease

Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

9:00AM-11:00AM: Abstract Number: 2912

Concomitant Kidney Disease in Patients with Lupus Nephritis

Systemic Lupus Erythematosus - Clinical Aspects and Treatment Poster Session III

9:00AM-11:00AM: Abstract Number: 2573

Confirmatory Analysis of Methylome Signatures in Rheumatoid Arthritis Using an Independent Dataset

Rheumatoid Arthritis - Animal Models Poster

9:00AM-11:00AM: Abstract Number: 2737

Consistency of Treatment Effects Across Different High-Risk Clinical Phenotypes in the Tofacitinib Clinical Program

Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy Poster III

9:00AM-11:00AM: Abstract Number: 2263

Construct and Convergent Validity of Four Global Measures of at-Work Productivity Loss in Patients with Rheumatic Diseases

Epidemiology and Public Health Poster III (ACR): Gout and Non-Inflammatory Musculoskeletal Conditions

9:00AM-11:00AM: Abstract Number: 2540

Construct Validity of the Promis-29 in Systemic Sclerosis: Results from the Scleroderma Patient-Centered Intervention Network (SPIN) Cohort

Research Methodology Poster (ARHP)

9:00AM-11:00AM: Abstract Number: 2543

Content Validity of the Improved Health Assessment Questionnaire in Knee Osteoarthritis Patients

Research Methodology Poster (ARHP)

9:00AM-11:00AM: Abstract Number: 2513

Contraception Use Amongst Women Ages 18-45 Taking Known Teratogenic Medications in an Academic Rheumatology Clinic

Reproductive Issues in Rheumatic Disorders: Basic and Clinical Aspects Poster Session

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].